权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel mouse models using MADR-GESTALT technology to accelerate glioma research

使用 MADR-GESTALT 技术加速神经胶质瘤研究的新型小鼠模型

基本信息

批准号：
10709379
负责人：
Linda M Liau
金额：
$ 23.56万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-11 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10709379
关键词：
Acceleration Affect Alleles Alternative Splicing Antigen Presentation Bar Codes Basic Science Brain Brain Neoplasms Cancer Patient Childhood Glioblastoma Chromatin Clinical Cytotoxic T-Lymphocytes Engineering Epidermal Growth Factor Receptor Epigenetic Process Evolution Genetic Glioblastoma Glioma Goals Heterogeneity Human Immune Evasion Immunocompetent Immunophenotyping Immunotherapeutic agent Immunotherapy Laboratories MHC Class I Genes Malignant neoplasm of brain Modeling Morbidity - disease rate Mus Mutation Oncogenic PDGFRA gene Pathology Patients Plasmids Pre-Clinical Model Preclinical Testing Proteins Radiation Recurrence Research Research Project Grants Scientist Series Site Structure System T cell therapy T-Cell Receptor TP53 gene Technology Testing Therapeutic Transgenes Translating Translational Research Tyrosine Kinase Receptor Inhibition Vaccines Work Yeasts antigen binding antigen-specific T cells chemotherapy clinical care driver mutation efficacy testing epidermal growth factor receptor VIII experimental study fascinate genome editing immune checkpoint blockade improved in vivo life history mosaic analysis mouse model mutant neoantigens novel novel strategies novel therapeutic intervention recombinase response small molecule inhibitor standard of care targeted treatment transcriptome treatment response tumor tumor microenvironment tumorigenesis

项目摘要

ABSTRACT (Project) The proposed experiments leverage novel mouse models created using MADR-GESTALT technology. These models will enhance information derived from in vivo experiments and are being applied in the following aims. Aim 1: Evaluate rational combinations of brain penetrant receptor tyrosine kinase inhibition and immunotherapy for study in new mouse models of oncogenically similar glioblastoma. This project will investigate mechanisms of immune evasion following treatment with immune-based therapy, and develop rational combinations of immunotherapeutic strategies to overcome the immunosuppressive milieu of the brain tumor micro-environment. Immunocompetent models that accurately recapitulate the known dominant oncogenic drivers in human GBM are crucial to this work. We propose to use the MADR-GESTALT system to create models of EGFRvIII-driven GBM in order to test how small molecule inhibitors can be effectively paired with active vaccines and checkpoint blockade immunotherapy. Aim 2: Evaluate the therapeutic potential of TCR-engineered cytotoxic T cells in H3G34R/V HGG. Previous research has identified a small number of tumor-associated neoantigens that are presented on class I MHC and are bound by antigen-specific T cell receptors in H3F3A mutant glioblastoma. H3F3A mutant and wild-type models will be used to further delve into the mechanisms by which these particular mutations affect oncogenesis in H3G34R glioblastoma, and will be used for pre-clinical testing of the efficacy of TCR-engineered adoptive T cell transfer as targeted therapy for H3F3A mutant glioblastoma.

摘要(项目) 拟议的实验利用了使用MADR-完形技术创建的新小鼠模型。这些模型将增强从活体实验中获得的信息，并将应用于以下目标。目的1：评价脑穿透性受体酪氨酸激酶抑制和免疫治疗的合理组合在致癌相似的胶质母细胞瘤的新小鼠模型上进行研究。这个项目将调查机制以免疫为基础的治疗后的免疫逃避，并开发合理的组合克服脑瘤微环境免疫抑制环境的免疫治疗策略。准确概括人类GBM中已知的显性致癌驱动因素的免疫活性模型对这项工作至关重要。我们建议使用MADR-完形系统来创建EGFRvIII驱动的模型为了测试小分子抑制剂如何有效地与活性疫苗和检查点配对封锁免疫疗法。目的：评价TCR基因工程细胞毒性T细胞对H3G34R/V HGG的治疗作用。上一首研究已经确定了一小部分肿瘤相关的新抗原，它们出现在I类MHC和在H3F3A突变型胶质母细胞瘤中被抗原特异性T细胞受体结合。H3F3A突变体和野生型这些模型将被用来进一步深入研究这些特定突变影响肿瘤发生的机制。在H3G34R胶质母细胞瘤中，并将用于临床前测试TCR工程过继T细胞的疗效细胞转移作为H3F3A突变型胶质母细胞瘤的靶向治疗